Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 5, 2021

Primary Completion Date

November 12, 2021

Study Completion Date

November 13, 2021

Conditions
Covid19
Interventions
DRUG

IV Dexamethasone

6 mg from Day 1 to 10 after randomization

DRUG

Nasal Dexamethasone

0.12 mg/kg/daily for 3 days from day 1, followed by 0.06 mg/kg/daily from day 4 to 10 after randomization.

Trial Locations (3)

14080

Instituto Nacional de Cardiología Ignacio Chávez, Mexico City

14269

El Instituto Nacional de Neurologia Y Neurocirugia Manuel Velasco Suarez, Mexico City

06720

Hospital General de Mexico Dr. Eduardo Liceaga, Mexico City

All Listed Sponsors
collaborator

Hospital General de México Dr. Eduardo Liceaga

OTHER_GOV

collaborator

Instituto Nacional de Cardiologia Ignacio Chavez

OTHER

collaborator

El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez

OTHER

lead

Edda Sciutto Conde

OTHER

NCT04513184 - Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19 | Biotech Hunter | Biotech Hunter